Modality
Cell Therapy
MOA
IL-23i
Target
CDK4/6
Pathway
Apoptosis
MG
Development Pipeline
Preclinical
Dec 2017
→ Sep 2028
PreclinicalCurrent
NCT05686557
1,993 pts·MG
2024-06→2028-09·Active
NCT05215308
1,609 pts·MG
2017-12→2025-06·Not yet recruiting
3,602 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-06-159mo agoInterim· MG
2026-10-207mo awayBTD· MG
2028-09-102.4y awayInterim· MG
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-06-15 · 9mo ago
MG
BTD
2026-10-20 · 7mo away
MG
Interim
2028-09-10 · 2.4y away
MG
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05686557 | Preclinical | MG | Active | 1993 | CfB |
| NCT05215308 | Preclinical | MG | Not yet recr... | 1609 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| STO-2663 | Stoke Ther | Approved | LAG-3 |